Holen Sie sich die Stockscreener-App
282.28
0.61%
-1.74
Handel nachbörslich:
282.56
0.28
+0.10%
Schlusskurs vom Vortag:
$284.02
Offen:
$281.98
24-Stunden-Volumen:
1.06M
Relative Volume:
0.75
Marktkapitalisierung:
$46.13B
Einnahmen:
$2.86B
Nettoeinkommen (Verlust:
$780.66M
KGV:
59.81
EPS:
4.72
Netto-Cashflow:
$1.19B
1W Leistung:
+2.65%
1M Leistung:
+0.46%
6M Leistung:
+25.02%
1J Leistung:
+40.13%
1-Tages-Spanne:
$280.79
$284.58
1-Wochen-Bereich:
$274.00
$286.07
52-Wochen-Spanne:
$196.09
$296.72
Veeva Systems Inc Stock (VEEV) Company Profile
Firmenname
Veeva Systems Inc
Sektor
Branche
Telefon
925-452-6500
Adresse
4280 HACIENDA DRIVE, PLEASANTON, CA
Vergleichen Sie VEEV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VEEV
Veeva Systems Inc
|
282.28 | 46.10B | 2.86B | 780.66M | 1.19B | 4.72 |
|
TEM
Tempus Ai Inc
|
76.71 | 13.63B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
64.13 | 12.35B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
91.06 | 7.74B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
35.75 | 6.32B | 906.14M | -52.62M | 89.62M | -0.3621 |
Veeva Systems Inc Stock (VEEV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-29 | Bestätigt | Needham | Buy |
| 2025-01-23 | Herabstufung | Goldman | Buy → Sell |
| 2024-12-20 | Eingeleitet | Stephens | Overweight |
| 2024-12-04 | Eingeleitet | Mizuho | Outperform |
| 2024-11-19 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-08 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2024-08-27 | Bestätigt | Citigroup | Buy |
| 2024-07-09 | Eingeleitet | BTIG Research | Buy |
| 2023-10-25 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-10-13 | Eingeleitet | Jefferies | Buy |
| 2023-06-28 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-06-01 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-17 | Herabstufung | Truist | Buy → Hold |
| 2023-02-23 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-01-04 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-12-06 | Eingeleitet | Cowen | Market Perform |
| 2022-12-02 | Bestätigt | Needham | Buy |
| 2022-10-31 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-10-19 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2022-07-27 | Eingeleitet | Oppenheimer | Outperform |
| 2022-06-23 | Eingeleitet | Goldman | Buy |
| 2022-06-21 | Fortgesetzt | Guggenheim | Buy |
| 2022-03-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-01-28 | Eingeleitet | Truist | Buy |
| 2022-01-07 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-06 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-16 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | Fortgesetzt | Stifel | Buy |
| 2021-09-02 | Bestätigt | BofA Securities | Buy |
| 2021-09-02 | Bestätigt | JMP Securities | Mkt Outperform |
| 2021-09-02 | Bestätigt | Needham | Buy |
| 2021-09-02 | Bestätigt | UBS | Neutral |
| 2021-07-21 | Eingeleitet | Cowen | Outperform |
| 2021-03-31 | Hochstufung | UBS | Sell → Neutral |
| 2021-01-07 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2020-12-09 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-10-14 | Fortgesetzt | UBS | Sell |
| 2020-08-28 | Bestätigt | Needham | Buy |
| 2020-07-23 | Eingeleitet | FBN Securities | Outperform |
| 2020-07-07 | Eingeleitet | Stephens | Overweight |
| 2020-06-08 | Eingeleitet | Citigroup | Buy |
| 2020-05-29 | Bestätigt | Needham | Buy |
| 2020-04-13 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-02-14 | Eingeleitet | Piper Sandler | Overweight |
| 2020-01-13 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-11-27 | Bestätigt | Canaccord Genuity | Hold |
| 2019-09-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-08-28 | Bestätigt | Needham | Buy |
| 2019-06-07 | Eingeleitet | Goldman | Neutral |
| 2019-05-30 | Bestätigt | BofA/Merrill | Buy |
| 2019-05-30 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2019-05-24 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-04-17 | Bestätigt | Needham | Buy |
| 2019-02-27 | Bestätigt | Needham | Buy |
Alle ansehen
Veeva Systems Inc Aktie (VEEV) Neueste Nachrichten
Veeva Systems Inc. (VEEV) is Attracting Investor Attention: Here is What You Should Know - sharewise.com
Veeva Systems' Strategic Legal Resolution with IQVIA and Its Implications for Cloud CRM in Life Sciences - AInvest
Veeva Systems Hits $270M Trading Volume at No 387 Rank as Shares Dip 0.12% Amid Barclays Buy Rating - AInvest
Veeva Systems Q2 Results Likely In-Line to Better, Maintain H2 Outlook, Truist Says - MarketScreener
Truist Raises Price Target on Veeva Systems to $268 From $230, Keeps Hold Rating - MarketScreener
Recovery Signals Appearing in Veeva Systems Inc. Charts2025 Stock Rankings & AI Powered Buy/Sell Recommendations - newsyoung.net
Veeva : The Path to Data-Driven Quality Management - MarketScreener
Traders Consider Averaging Down in Veeva Systems Inc.2025 AllTime Highs & Daily Stock Momentum Reports - classian.co.kr
Veeva Systems and IQVIA Settle Litigation, Announce Partnership - MSN
Veeva's 0.8% Rally on 341st-Ranked $290M Volume as Legal Spat with IQVIA Turns into Global Partnership - AInvest
IQVIA Shares Slide 0.1% on $210M Trade Volume Ranks 459th as Landmark Veeva Partnership Resolves Legal Disputes and Unleashes AI-Driven Synergies - AInvest
Veeva Systems And IQVIA End Feud, Clearing The Way Forward - Finimize
IQVIA, Veeva Forge Long-Term Clinical and Commercial Partnerships - Medical Product Outsourcing
Veeva Systems: A Top Growth Stock for Long-Term Investors - AInvest
Veeva Systems, IQVIA Dispute Resolution Clears Investor Concerns Over CRM Data Risk: Oppenheimer - AInvest
Veeva Systems, IQVIA Dispute Resolution Removes Investor Concerns Around CRM Data Risk, Oppenheimer Says - MarketScreener
Is Veeva Systems Inc. Forming a Consolidation BasePortfolio Return Summary & Fast Exit/Entry Strategy Plans - newsyoung.net
Why Veeva Systems (VEEV) is a Top Growth Stock for the Long-Term - Yahoo Finance
Veeva and IQVIA Unveil Global Clinical Partnership as Trading Volume Surges 52.22% to 259th Rank - AInvest
IQVIA and Veeva’s Strategic Alliance Spikes Trading Volume 41.85% as Stock Jumps into Top 500 List - AInvest
Life Sciences Data Rivals Settle Trade Secrets Battle - Law360
Healthcare Triangle, Inc. shares rise 1.21% after-hours following IQVIA and Veeva's global partnership announcement. - AInvest
IQVIA and Veeva Form Long-term Partnerships, Resolve All Disputes - AInvest
Iqvia and Veeva Form Global Partnership, Settle Legal Disputes - AInvest
Veeva Systems and IQVIA settle litigation with mutual data access agreements By Investing.com - Investing.com South Africa
Veeva Systems and IQVIA settle litigation with mutual data access agreements - Investing.com Australia
IQVIA, Veeva Announce Long-term Clinical & Commercial Partnerships - Contract Pharma
IQVIA and Veeva Announce Long-term Clinical and Commercial Partnerships and Resolution of All Disputes - Veeva
IQVIA and Veeva Announce Long-term Clinical and Commercial Partnerships and Resolution of All Disputes | VEEV Stock News - GuruFocus
IQVIA, Veeva announce global clinical and commercial partnerships. - AInvest
IQVIA and Veeva Announce Long-term Clinical and Commercial Partnerships - AInvest
Should You Invest in Veeva (VEEV) Based on Bullish Wall Street Views? - MSN
Veeva Systems Inc. (NYSE:VEEV) Q3 2025 Earnings Call Transcript - MSN
Is Veeva Systems Inc. stock risky to hold now2025 Year in Review & Reliable Entry Point Alerts - thegnnews.com
Veeva Systems Rises 2.05% on $230M Volume (Rank 440) as 16.7% Revenue Growth and Institutional Buys Outpace Insider Sales - AInvest
Is Veeva Systems Inc. stock suitable for long term investing2025 Pullback Review & Consistent Profit Trade Alerts - 선데이타임즈
What Technical Tools Say About Veeva Systems Inc. RecoveryJuly 2025 Trade Ideas & Technical Entry and Exit Tips - newsyoung.net
Veeva to Release Fiscal 2026 Second Quarter Results on August 27, 2025 - 富途牛牛
Veeva Systems (VEEV) Exceeds Market Returns: Some Facts to Consider - sharewise.com
Veeva Systems Inc.'s (NYSE:VEEV) Stock's On An Uptrend: Are Strong Financials Guiding The Market? - 富途牛牛
Veeva Systems (VEEV) Declines More Than Market: Some Information for Investors - MSN
Reasons to Add Veeva Systems Stock to Your Portfolio for Now - MSN
Veeva Systems Shares Dip 0.55% as Trading Volume Surges 60% to 310th Rank - AInvest
Reasons To Add Veeva Systems Stock To Your Portfolio For Now - Barchart.com
Research Shows Medtechs Prioritizing Site Collaboration and Data Quality - Veeva
Veeva Systems shares rise 1.16% premarket after announcing findings from the 2025 Veeva MedTech Clinical Benchmark. - AInvest
Research Shows Medtechs Prioritizing Site Collaboration And Data Quality - Barchart.com
eClinical Solutions Market Key Players AnalysisMedidata, Veeva Systems, Iqvia Inc., Icon Plc, Signant Health. - openPR.com
Veeva Systems Dips on 469th-Ranked Volume as Institutions Boost Holdings Amid Insider Share Sales - AInvest
2 Reasons to Watch VEEV and 1 to Stay Cautious - ca.finance.yahoo.com
Veeva Systems Inc. (VEEV) Is a Trending Stock: Facts to Know Before Betting on It - MSN
Finanzdaten der Veeva Systems Inc-Aktie (VEEV)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.68%
0.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):